The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hlL-6R). The formulations may contain, in addition to an anti-hlL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
